AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
PTC Therapeutics
Acquired Company
Sangamo Therapeutics
South PlainfieldBrisbaneBiotechnologyBiotechnologyHealth CareGeneticsTherapeuticsDescription
PTC Therapeutics, Inc. has completed its acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics, Inc. Following this acquisition, PTC plans to complete a rolling BLA submission for ST-920 to the FDA by Q4 2026. This therapy represents a significant advancement in treating Fabry disease, addressing limitations of chronic enzyme replacement therapies.
Fundz sees it the moment PTC Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Sangamo Therapeutics?
Sangamo Therapeutics was acquired by PTC Therapeutics, based in South Plainfield. The deal was reported on September 21, 2026. PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development and commercialization of small-molecule drugs. PTC Therapeutics is publicly traded (PTCT) and operates in Biotechnology.
When did PTC Therapeutics acquire Sangamo Therapeutics?
PTC Therapeutics's acquisition of Sangamo Therapeutics was reported on September 21, 2026. PTC Therapeutics, Inc. has completed its acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics, Inc. Following this acquisition, PTC plans to complete a rolling BLA submission for ST-920 to the FDA by Q4 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sangamo Therapeutics do?
Sangamo Therapeutics, Inc. is a genomic medicine company based in California. It is publicly traded (SGMOQ), operating in Biotechnology, and is based in Brisbane.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.